organ transplantation, neuroscience, etc.
Novartis India Limited has submitted its investor presentation detailing the operational strategies and business roadmap for its pharmaceutical platform. The update highlights the multi-decade heritage and established prescriber equity of flagship brands like Voveran, Methergin, Calcium-Sandoz, and Tegrital, which maintain leadership positions across priority therapeutic areas. The company's strategic focus...
Novartis India Limited has announced that its upcoming Seventy-Eighth Annual General Meeting will be conducted virtually through video conferencing and other audio-visual means. Shareholders have been informed regarding the dispatch of letters containing the web-link to access the comprehensive Annual Report for the financial year. Additionally, shareholders holding physical securities...
Novartis India Ltd has announced an upcoming investor and analyst meeting to engage with institutional stakeholders. The interaction will be held in a hybrid format, allowing both virtual and physical participation from Mumbai. Management has clarified that discussions will strictly rely on publicly available information, ensuring no unpublished price-sensitive data...
Novartis India Ltd has entered into an exclusive promotion and distribution agreement for a total upfront consideration of 10 Cr. Under this deal, the company secures exclusive rights to promote and distribute a retina portfolio comprising Accentrix and Pagenax across India. This strategic move marks the company’s entry into the...
Novartis India is acquiring the trademarks 'Minipress' and 'Minipres' along with related IP from Pfizer for INR 1,250.0001 Cr. The acquired brand brings solid revenue backing and expands Novartis's footprint in cardiovascular and urology portfolios. A strong strategic portfolio addition for long-term growth.
